Trial Design Issues, Failure To Follow Guidance Likely to Hurt Merck At Keytruda Advisory Panel

 
• By Sarah Karlin-Smith
Molecular model of Keytruda
FDA is asking an advisory panel whether Merck's Keytruda needs more data before a regulatory decision for triple-negative breast cancer can be made • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers